Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left…
Premier Health Reports 2025 First Quarter Results
MONTRÉAL, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc.…
4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones
February 28, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc. Presented…
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on…
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
February 27, 2025 07:00 ET | Source: Beta Bionics, Inc. IRVINE, Calif.,…
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025 07:00 ET | Source: C4 Therapeutics, Inc. Planning Activities…
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30…
The Adecco Group: Q4 & FULL YEAR 2024 RESULTS
Market share gains; strong cash generation; above target G&A savings driving resilient…
ASM announces fourth quarter 2024 results
Almere, The NetherlandsFebruary 25, 2025, 6 p.m. CET Eighth consecutive year of…
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the…